Halozyme Therapeutics, Inc.
HALO · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $6 | $5 | $8 | $6 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $2 | $1 | $2 | $1 |
| Enterprise Value | $7 | $6 | $9 | $6 |
| Revenue | $1 | $1 | $1 | $0 |
| % Growth | 22.4% | 25.6% | 48.9% | – |
| Gross Profit | $1 | $1 | $1 | $0 |
| % Margin | 84.3% | 76.8% | 78.9% | 81.6% |
| EBITDA | $1 | $0 | $0 | $0 |
| % Margin | 64.7% | 54.5% | 47.8% | 58.4% |
| Net Income | $0 | $0 | $0 | $0 |
| % Margin | 43.7% | 34% | 30.6% | 90.8% |
| EPS Diluted | 3.43 | 2.1 | 1.44 | 2.74 |
| % Growth | 63.3% | 45.8% | -47.4% | – |
| Operating Cash Flow | $0 | $0 | $0 | $0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | $0 | $0 | $0 | $0 |